The price difference between Ozempic and Mounjaro almost never decides your monthly cost. Both list above a thousand dollars a month, and few people pay list. What you actually pay is set by whether the prescription is for type 2 diabetes or for weight, whether your plan covers that use, whether you qualify for a manufacturer savings card, and which self-pay route you land on if coverage is denied. Two people prescribed the same drug in the same month can pay amounts that differ tenfold.
Are these the same drugs people use for weight loss?
This is the first source of confusion in any ozempic vs mounjaro conversation. Ozempic is semaglutide, approved for type 2 diabetes. Mounjaro is tirzepatide, also approved for type 2 diabetes. The same molecules are sold under different brand names for chronic weight management: semaglutide as Wegovy and tirzepatide as Zepbound. The FDA has published guidance clarifying which products contain semaglutide and how the diabetes and weight-loss versions differ, and reading that before you shop matters, because the brand on the box changes both the approved use and the assistance programs you can reach.
The trial evidence sits under the weight brands, not under Ozempic and Mounjaro directly, though the molecules are shared. Semaglutide’s effect on weight has been studied across the STEP program, and tirzepatide’s across SURMOUNT. Those are separate research programs, not a head-to-head, so anyone claiming one brand “beat” the other is usually overstating what the data supports.
Is coverage a drug decision or a category decision?
For diabetes, coverage is usually driven by diagnosis and formulary tier. A person with type 2 diabetes often finds one or both drugs covered, with cost set by tier placement, deductible, and prior authorization. For weight, coverage is a category decision, and many commercial plans exclude anti-obesity medication outright. When that exclusion applies, it applies to the whole category, so switching from one brand to the other produces the same denial.
This is why the first question is not “which is cheaper” but “what is this being prescribed for, and does my plan cover that.” Medicare adds a further complication, since Part D has historically been barred from covering drugs used only for weight loss, while the same drug prescribed for diabetes may be covered. Check the category and the indication first. The brand comparison restarts on entirely different numbers depending on the answer.
See also: Truck House Life Net Worth: The Net Worth of Truck House Life Explained
What are the routes to a price?
| Route | What sets the number | Main limitation |
|---|---|---|
| Covered benefit | Formulary tier, deductible, coinsurance | Requires the plan to cover the use |
| Manufacturer savings card | Commercial insurance status, eligibility rules | Usually excludes government insurance |
| Manufacturer self-pay | Fixed cash price set by the maker | Conditions on refill timing and dose |
| Compounded medication | Pharmacy and provider pricing | Not an FDA-approved product |
Why are savings cards narrower than they look?
Both Novo Nordisk and Eli Lilly run savings programs, and both are commonly misread. The headline figure usually assumes commercial insurance that already covers the drug, with the card trimming the remaining copay. Someone whose plan excludes the use rarely qualifies for the largest advertised reduction, and people on Medicare or Medicaid are generally shut out of commercial copay assistance entirely. The Ozempic and Mounjaro diabetes cards also tend to have different terms from the Wegovy and Zepbound weight cards, so a figure quoted for one does not carry over. Read the eligibility conditions before treating an advertised price as your price.
How did self-pay programs change the comparison?
Both makers now sell certain products directly to cash-paying patients below list, and platforms like NovoCare and LillyDirect have made that route more visible. These programs bring brand medication within reach of people who would once have been priced out, and they narrowed the gap that used to make compounded products the only realistic option. They also carry conditions. Refill-timing rules are common, and pricing can shift by dose or by whether enrollment stays active, so the figure that matters is the one you can sustain month after month, not the introductory one.
Where does compounded medication fit?
Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than made under an approved application. They are not FDA-approved products, and they have not been through the process that generated the trial evidence for the brands. That is a real distinction, not a technicality. What they often offer is a predictable monthly cash price with insurance kept out of the loop. Telehealth practices such as Ro, Hims and Hers, Henry Meds, and FormBlends publish flat monthly pricing for supervised prescribing, and readers weighing that option can find the full details here alongside how it compares to the brand routes. Prescribing there is handled by a licensed clinician rather than sold directly as a product.
The honest framing is that compounded medication trades regulatory assurance for cost predictability. Whether that trade is reasonable depends on the person, and it belongs with a prescriber who knows the case. It is not a discount version of Ozempic or Mounjaro.
What does the maintenance evidence say about stopping?
Cost planning should account for how long these drugs are meant to be taken. The STEP 4 trial found that people who continued semaglutide kept losing weight, while those switched to placebo regained much of it. The STEP 1 extension showed substantial weight regain and reversal of cardiometabolic gains after withdrawal, and SURMOUNT-4 reported a similar pattern for tirzepatide, with continued treatment maintaining reduction and withdrawal reversing it. STEP 3 and STEP 8 add context on semaglutide combined with behavioral therapy and against an older comparator, and SURMOUNT-CN extends tirzepatide findings to a different population. The practical point is that budgeting for a few months rarely matches how the medications work.
Where does most of the delay live?
Where a plan does cover the use, approval is rarely automatic. Prior authorization often asks for diagnosis documentation, sometimes prior therapy history, and for weight indications a body mass index and often a related condition. Assembling that paperwork is the step that most often adds weeks between prescription and first dose. Denials are frequently appealable, and a meaningful share are overturned once the clinical record is complete. Treating a first denial as final is a common and expensive mistake.
Key takeaways
- Ozempic and Mounjaro are approved for diabetes; the weight brands are Wegovy and Zepbound.
- Coverage turns on the indication and the category, so a brand swap rarely fixes a denial.
- Savings cards mostly help people who already have commercial coverage.
- Manufacturer self-pay and compounded routes are what cash payers actually compare.
- The sustainable monthly price matters more than the first month’s promotion.
Frequently asked questions
Is Ozempic or Mounjaro reliably cheaper?
Not in a way that generalizes. Both carry list prices above a thousand dollars a month, and what a person pays depends far more on coverage status and which assistance route they use than on which drug is prescribed.
Why does my plan cover one but not the other?
Both are approved for type 2 diabetes, and coverage there is usually driven by diabetes diagnosis and formulary placement. Coverage for weight is separate, and many plans exclude weight management as a category, which affects both products at once.
Do savings cards work without insurance?
Usually not as advertised. Commercial copay cards generally assume existing commercial coverage and exclude people with government insurance. Manufacturer self-pay programs are the route built for cash payers.
Is compounded medication just a cheaper version of Ozempic or Mounjaro?
No. It is prepared by a compounding pharmacy and is not an FDA-approved product. It may contain the same active molecule, but it has not gone through the approval process behind the published trial evidence.
What should be checked before comparing prices at all?
Whether the prescription is for diabetes or for weight, and whether the plan covers that use. That answer decides which pricing route applies, and a brand comparison is only meaningful inside a single route.
